Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases

Ann Rheum Dis. 2020 Dec;79(12):1659-1661. doi: 10.1136/annrheumdis-2020-218054. Epub 2020 Jun 30.
No abstract available

Keywords: autoimmune diseases; biological therapy; glucocorticoids.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antirheumatic Agents / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • Arthritis, Psoriatic / complications
  • Arthritis, Psoriatic / drug therapy
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy
  • Azithromycin / therapeutic use
  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • Cohort Studies
  • Coronavirus Infections / complications
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / mortality
  • Coronavirus Infections / physiopathology*
  • Coronavirus Infections / therapy
  • Drug Combinations
  • Female
  • Glucocorticoids / therapeutic use*
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Factors / therapeutic use*
  • Lopinavir / therapeutic use
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / drug therapy
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / mortality
  • Pneumonia, Viral / physiopathology*
  • Pneumonia, Viral / therapy
  • Retrospective Studies
  • Rheumatic Diseases / complications
  • Rheumatic Diseases / drug therapy*
  • Ritonavir / therapeutic use
  • SARS-CoV-2
  • Severity of Illness Index
  • Spondylarthropathies / complications
  • Spondylarthropathies / drug therapy

Substances

  • Antirheumatic Agents
  • Antiviral Agents
  • Drug Combinations
  • Glucocorticoids
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Hydroxychloroquine
  • Azithromycin
  • Ritonavir